Menu Search
Equities

Monopar Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1IY0:MUN

Monopar Therapeutics Inc

Actions
  • Price (EUR)49.20
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change0.00%
  • Beta1.5754
Data delayed at least 15 minutes, as of Feb 13 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

  • Revenue in USD (TTM)0.00
  • Net income in USD-19.44m
  • Incorporated2014
  • Employees16.00
  • Location
    Monopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
  • Phone+1 (847) 388-0349
  • Fax+1 (302) 655-5049
  • Websitehttps://www.monopartx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.